Association of MDR1 and ERCC1 Polymorphisms with Response and Toxicity to Cisplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer Patients

Strategic Insights -

Researchers have made new discoveries in non-small cell lung cancer (NSCLC) regarding the association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy. The study, conducted by S. Chen and colleagues, aimed to investigate the relationship between genetic variations and drug resistance in NSCLC patients. The team found that polymorphisms in the MDR1 gene were associated with a significantly increased risk of drug resistance and gastrointestinal toxicity, but not hemato-, hepato-, or nephro-toxicities. The study's findings have significant implications for the treatment of NSCLC and the development of predictive markers for treatment response.

Key Takeaways:

  • Researchers investigated the association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in 95 NSCLC patients with advanced disease.
  • The study found that patients carrying at least one variant MDR1 2677 T allele had a significantly increased risk of drug resistance (OR=1.844, 95% CI=1.01-3.53, p=0.04).
  • The same allele was associated with a significantly increased risk of gastrointestinal toxicity (p=0.03) but not hemato-, hepato-, or nephro-toxicities.
  • Patients harboring the E1/-129T-2677T-3435C haplotype had a significantly better response to chemotherapy compared with those having the other haplotypes (p=0.02, 95% CI=1.20-25.87).
  • The study's findings suggest that MDR1 gene polymorphisms may be a predictive marker of platinum-based treatment response and of secondary effects, particularly gastrointestinal toxicity.

Statistics:

  • 95 NSCLC patients with advanced disease were recruited for the study.
  • 1.844: the odds ratio for the association between MDR1 2677 T allele and drug resistance.
  • 1.01-3.53: the 95% confidence interval for the odds ratio.
  • 0.04: the p-value for the association between MDR1 2677 T allele and drug resistance.
  • 0.03: the p-value for the association between MDR1 2677 T allele and gastrointestinal toxicity.

Sources:

  • Chen, S., et al. (2010). Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. International Journal of Hygiene and Environmental Health, 213(2), 140-145.
  • Non-Small Cell Lung Cancer Risk Factors. (n.d.). Retrieved from
  • Shantou University Medical College. (n.d.). Analytical Cytology Laboratory. Retrieved from